Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07357727 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 460
- Enrollment target
NCT07357727 is a Phase 3 study that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 460 participants.
The verdict
NCT07357727, a Phase 3 study, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 460 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxolitinib alone in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have not previously received Janus kinase (JAK) inhibitor therapy.
Interventions
- DRUG Placebo
- DRUG Pelabresib
- DRUG Ruxolitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Start Date | 2026-06-12 |
| Est. Completion | 2030-12-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07357727
The ClinicalTrials.gov registry entry for NCT07357727 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 460 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07357727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07357727 about?
NCT07357727 is a clinical study titled "A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)". The purpose of this trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxolitinib alone in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia ...
What is the current status of trial NCT07357727?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 460 participants. The study started on 2026-06-12. Estimated completion is 2030-12-27.
What interventions are being tested in trial NCT07357727?
The interventions under investigation include: Placebo (DRUG), Pelabresib (DRUG), Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT07357727?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.